SCM
SLNO

Silverarc Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Silverarc Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-42,500
Closed -$3.04M – 82
2025
Q1 		$3.04M Buy
+42,500
New +$2.07M 0.62% 47

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Silverarc Capital Management's SLNO Position: Q1 2026 in Review

Silverarc Capital Management sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 117,485 shares — an estimated $5.44M sold.

Silverarc Capital Management first reported a position in SLNO in Q4 2020 and held it in 8 quarters. The position peaked at $17.1M in Q2 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Silverarc Capital Management reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Silverarc Capital Management sold 117,485 Soleno Therapeutics shares in Q1 2026, an estimated $5.44M.
  • Silverarc Capital Management first reported a position in Soleno Therapeutics in Q4 2020 and held it in 8 quarters.
  • Silverarc Capital Management's Soleno Therapeutics position peaked at $17.1M in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Silverarc Capital Management's 13F filing for Q1 2026, filed 14 May 2026.